Genetic Variant Boosts Risk of GVHD in Allogeneic Transplants

According to a new study published in the New England Journal of Medicine, the risk of developing graft versus host disease (GVHD) following an allogeneic stem cell transplant is significantly increased in patients with a specific genetic variant.

The genetic variant is associated with increased expression of the HLA-DPB1 gene.

Specifically, patients who are found through genotyping to have the high-expression rs9277534G allele are at a 54 percent greater risk of developing GVHD following HLA-mismatched transplants compared with patients who have the corresponding low-expression rs9277534A allele.

Furthermore, the risk of death from causes other than disease recurrence was found to be 25 percent higher in patients undergoing transplants who have the high-expression allele.

“Our data provide new information on the role of HLA-DPB1 expression in transplantation associated risks that can be used to guide the selection of donors for future transplant recipients in order to minimize the risk of acute GVHD," concluded Effie Petersdorf MD of Fred Hutchinson Cancer Research Center in Seattle and co-authors. "We discovered that if rs9733534 genotypes had been known at the time of the search for an unrelated donor, almost 55% of recipients with rs9277534AG would have had suitable donors, and mismatching for their G-linked HLA-DPB1 allele could have been avoided."

The research team also concluded that the donors of choice for patients receiving an allogeneic transplant remain fully HLA-matched donors with the high-expression allele, and that they believed their study supported genotyping for both rs9277534 and HLA-DPB1 in the donor selection process.

Source: MedPage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap